Uplinza

Made by

• Mitsubishi Tanabe Pharma

Active Ingredient

Inebilizumab (genetical recombination)

Prospectus

Approval date

2021/3/23

Treats

• Neuromyelitis optica, Devic disease

Dosages

• UPLIZNA for Intravenous Infusion - 3495304円／瓶